CN101766551B - Drug toothpaste for treating oral diseases and preparation method thereof - Google Patents
Drug toothpaste for treating oral diseases and preparation method thereof Download PDFInfo
- Publication number
- CN101766551B CN101766551B CN2010101352993A CN201010135299A CN101766551B CN 101766551 B CN101766551 B CN 101766551B CN 2010101352993 A CN2010101352993 A CN 2010101352993A CN 201010135299 A CN201010135299 A CN 201010135299A CN 101766551 B CN101766551 B CN 101766551B
- Authority
- CN
- China
- Prior art keywords
- weight portion
- toothpaste
- drug
- paeonol
- drop
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 229940034610 toothpaste Drugs 0.000 title claims abstract description 35
- 239000000606 toothpaste Substances 0.000 title claims abstract description 35
- 239000003814 drug Substances 0.000 title claims abstract description 22
- 208000025157 Oral disease Diseases 0.000 title claims abstract description 18
- 208000030194 mouth disease Diseases 0.000 title claims abstract description 18
- 229940079593 drug Drugs 0.000 title abstract description 9
- 238000002360 preparation method Methods 0.000 title abstract description 9
- UILPJVPSNHJFIK-UHFFFAOYSA-N Paeonol Chemical compound COC1=CC=C(C(C)=O)C(O)=C1 UILPJVPSNHJFIK-UHFFFAOYSA-N 0.000 claims abstract description 42
- YLTGFGDODHXMFB-UHFFFAOYSA-N isoacetovanillon Natural products COC1=CC=C(C(C)=O)C=C1O YLTGFGDODHXMFB-UHFFFAOYSA-N 0.000 claims abstract description 22
- MLIBGOFSXXWRIY-UHFFFAOYSA-N paeonol Natural products COC1=CC=C(O)C(C(C)=O)=C1 MLIBGOFSXXWRIY-UHFFFAOYSA-N 0.000 claims abstract description 22
- 238000000034 method Methods 0.000 claims abstract description 8
- 230000008569 process Effects 0.000 claims abstract description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 25
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 claims description 22
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- BDAGIHXWWSANSR-NJFSPNSNSA-N hydroxyformaldehyde Chemical compound O[14CH]=O BDAGIHXWWSANSR-NJFSPNSNSA-N 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 13
- 229910000018 strontium carbonate Inorganic materials 0.000 claims description 13
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 claims description 13
- 229960000401 tranexamic acid Drugs 0.000 claims description 13
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 12
- 239000004323 potassium nitrate Substances 0.000 claims description 11
- 235000010333 potassium nitrate Nutrition 0.000 claims description 11
- 239000003292 glue Substances 0.000 claims description 9
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 claims description 8
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 claims description 8
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 8
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 8
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 8
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 8
- 229960000458 allantoin Drugs 0.000 claims description 8
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims description 8
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 8
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 8
- 235000019700 dicalcium phosphate Nutrition 0.000 claims description 8
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 8
- 229960000502 poloxamer Drugs 0.000 claims description 8
- 229920001983 poloxamer Polymers 0.000 claims description 8
- 229940085605 saccharin sodium Drugs 0.000 claims description 8
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 8
- 239000000600 sorbitol Substances 0.000 claims description 8
- WGIWBXUNRXCYRA-UHFFFAOYSA-H trizinc;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Zn+2].[Zn+2].[Zn+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O WGIWBXUNRXCYRA-UHFFFAOYSA-H 0.000 claims description 8
- 239000000230 xanthan gum Substances 0.000 claims description 8
- 229920001285 xanthan gum Polymers 0.000 claims description 8
- 229940082509 xanthan gum Drugs 0.000 claims description 8
- 235000010493 xanthan gum Nutrition 0.000 claims description 8
- 239000011746 zinc citrate Substances 0.000 claims description 8
- 229940068475 zinc citrate Drugs 0.000 claims description 8
- 235000006076 zinc citrate Nutrition 0.000 claims description 8
- 239000007864 aqueous solution Substances 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 239000000377 silicon dioxide Substances 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 5
- 235000012239 silicon dioxide Nutrition 0.000 claims description 4
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 3
- 238000013019 agitation Methods 0.000 claims description 3
- 239000006071 cream Substances 0.000 claims description 3
- 238000007599 discharging Methods 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 15
- 239000000126 substance Substances 0.000 abstract description 7
- 208000004371 toothache Diseases 0.000 abstract description 6
- 239000004615 ingredient Substances 0.000 abstract description 5
- 230000003266 anti-allergic effect Effects 0.000 abstract description 4
- 230000036541 health Effects 0.000 abstract description 3
- 230000006870 function Effects 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 230000000857 drug effect Effects 0.000 abstract 2
- 230000001194 anti-hemostatic effect Effects 0.000 abstract 1
- 206010003246 arthritis Diseases 0.000 abstract 1
- 229940126678 chinese medicines Drugs 0.000 abstract 1
- 230000007794 irritation Effects 0.000 abstract 1
- 230000007774 longterm Effects 0.000 abstract 1
- 201000001245 periodontitis Diseases 0.000 description 6
- 230000008859 change Effects 0.000 description 4
- HNNQYHFROJDYHQ-UHFFFAOYSA-N 3-(4-ethylcyclohexyl)propanoic acid 3-(3-ethylcyclopentyl)propanoic acid Chemical compound CCC1CCC(CCC(O)=O)C1.CCC1CCC(CCC(O)=O)CC1 HNNQYHFROJDYHQ-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 108010088842 Fibrinolysin Proteins 0.000 description 3
- FHHAOPXGDLWQQM-UHFFFAOYSA-N N.[K] Chemical compound N.[K] FHHAOPXGDLWQQM-UHFFFAOYSA-N 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 238000000586 desensitisation Methods 0.000 description 3
- 229940001501 fibrinolysin Drugs 0.000 description 3
- 229930182470 glycoside Natural products 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 102000013566 Plasminogen Human genes 0.000 description 2
- 108010051456 Plasminogen Proteins 0.000 description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
- 241001279158 Silonia silondia Species 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000036592 analgesia Effects 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000000498 cooling water Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- -1 paeonol glycoside Chemical class 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000004575 stone Substances 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- YKRGDOXKVOZESV-WRJNSLSBSA-N Paeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)OC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-WRJNSLSBSA-N 0.000 description 1
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 1
- 102000018120 Recombinases Human genes 0.000 description 1
- 108010091086 Recombinases Proteins 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- MSJIBCNUPFPONA-UHFFFAOYSA-N [K].[Sr] Chemical compound [K].[Sr] MSJIBCNUPFPONA-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229960003375 aminomethylbenzoic acid Drugs 0.000 description 1
- QCTBMLYLENLHLA-UHFFFAOYSA-N aminomethylbenzoic acid Chemical compound NCC1=CC=C(C(O)=O)C=C1 QCTBMLYLENLHLA-UHFFFAOYSA-N 0.000 description 1
- 230000002804 anti-anaphylactic effect Effects 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 230000006957 competitive inhibition Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 210000004268 dentin Anatomy 0.000 description 1
- 238000011981 development test Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- QMTMGAFMAXPXDN-UHFFFAOYSA-N naphtho[1,2-g][1]benzofuran-10,11-dione Chemical compound C1=CC=CC2=C(C(C(=O)C3=C4OC=C3)=O)C4=CC=C21 QMTMGAFMAXPXDN-UHFFFAOYSA-N 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- YKRGDOXKVOZESV-UHFFFAOYSA-N paeoniflorin Natural products O1C(C)(C2(CC34)OC5C(C(O)C(O)C(CO)O5)O)CC3(O)OC1C24COC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-UHFFFAOYSA-N 0.000 description 1
- 230000037324 pain perception Effects 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000004499 secondary dentin Anatomy 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 229910001427 strontium ion Inorganic materials 0.000 description 1
- 159000000008 strontium salts Chemical class 0.000 description 1
- PWYYWQHXAPXYMF-UHFFFAOYSA-N strontium(2+) Chemical compound [Sr+2] PWYYWQHXAPXYMF-UHFFFAOYSA-N 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000003815 supercritical carbon dioxide extraction Methods 0.000 description 1
- 238000000194 supercritical-fluid extraction Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229940095688 toothpaste product Drugs 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
Abstract
The invention relates to drug toothpaste for treating oral diseases and a preparation method thereof. The drug toothpaste is new type toothpaste adopting Chinese medicines including paeonol, and the like as main drug-effect ingredients and serving with anti-allergic and anti-hemostatic drug-effect ingredients. Compared with other chemical synthetic drugs, the drug toothpaste has the characteristics of small irritation and small toxic and side effects. The drug toothpaste has the functions for treating oral diseases, such as dental arthritis, toothache, hemodia, and the like. With long-term use, the drug toothpaste can improve oral environment and maintains oral health. The drug toothpaste has the advantages of reasonable formula, simple process and significant effect.
Description
Technical field
The present invention relates to a kind of medicated toothpaste and preparation method thereof, particularly a kind of medicated toothpaste that is used to treat oral disease and preparation method thereof.
Background technology
Periodontitis, toothache, oral diseases such as hemodia are perplexing people's life always; Chinese herbal toothpaste kind in the market is a lot, and its active ingredient is compared other chemical synthetic drug mostly from natural animal-plant, and it is little to have zest, and the characteristics that toxic and side effects is little are accepted extensively by people; It mainly is in the lotion of toothpaste substrate of forming toothpaste, to add corresponding Chinese medicine ingredients to form Chinese medicinal toothpaste, though these compositions have certain inhibition oral cavity noxious bacteria, and control periodontitis, the effect of anti-inflammatory analgesic; But possess multi-efficiency at present, the toothpaste that comprehensively solves oral disease is actually rare.
Therefore, provide a kind of convenient in application, obvious results to be used to medicated toothpaste of treating oral disease and preparation method thereof, promptly become one of these those skilled in the art problem anxious to be addressed.
Summary of the invention
The objective of the invention is to overcome above-mentioned weak point, provide a kind of obvious results to be used to medicated toothpaste of treating oral disease and preparation method thereof.
Following for realizing the embodiment that above-mentioned purpose the present invention adopted:
A kind of medicated toothpaste that is used to treat oral disease is characterized in that this medicated toothpaste is prepared from following composition:
The composition parts by weight
Glycerol 10-20;
Sorbitol 20-30;
Xanthan gum 0.5-2;
Cellulose gum 0.1-1;
Poloxamer 1-3;
Saccharin sodium 0.1-0.5;
Methyl hydroxybenzoate 0.1-0.5;
Sodium lauryl sulfate 1-3;
Allantoin 1-3;
Paeonol 0.1-1;
Potassium nitrate 1-5;
Tranexamic acid 0.01-0.1;
Strontium carbonate 0.5-2;
Silica 1-6;
Calcium hydrogen phosphate 20-30;
Zinc citrate 0.5-2;
Essence 1-2;
Light blue 0.0002-0.0005;
Water 8-10.
A kind of method for preparing that is used to treat the medicated toothpaste of oral disease, the practical implementation step is following:
Step (1) glue:
After the water of the said weight portion of input and poloxamer dissolve fully in agitated reactor, drop into sorbitol, sodium lauryl sulfate, methyl hydroxybenzoate, allantoin, tranexamic acid, the light blue of said weight portion again, fully dissolving was left standstill 20 minutes;
The saccharin sodium of said weight portion is dissolved in 80 ℃ of hot water to dissolving fully, in the input agitated reactor of filtration back;
In premixed device, drop into the glycerol of said weight portion, drop into cellulose gum, xanthan gum, the paeonol of said weight portion again, this mixture back that is uniformly dispersed is dropped in the agitated reactor and evenly stirred 15 minutes with aforementioned mixing of materials, it is subsequent use to process the glue discharging;
Said weight portion potassium nitrate, strontium carbonate are dissolved in 80 ℃ of hot water, stir dissolving back input agitated reactor fully, agitation cycle 20 minutes, this aqueous solution is subsequent use;
Step (2) system cream:
Open cooling water, energized is opened air compressor as the operational power source;
After glue that step (1) is made and aqueous solution add Manufacturing medicine extract machine fully, add powder again and go into Manufacturing medicine extract machine, when adding powder, add said weight portion zinc citrate, silicon dioxide earlier, add the calcium hydrogen phosphate and the essence of said weight portion again, stir; The check of regularlying sample, fill.
The present invention chooses following raw material and explains as main functional component and pharmacology thereof:
(A) paeonol; " Cortex Moutan (CORTEX MOUTAN) " obtains through supercritical carbon dioxide extraction for conventional Chinese medicine.
Put down in writing in the Cortex Moutan Compendium of Material Medica: control the few the moon of brothers, faint cloudy four through blood system volt fire.Wherein main component comprises paeonol, paeonol glycoside, the former glycoside of paeonol (paeonol glycoside ten arabinose), paeoniflorin.The traditional Chinese medical science thinks that it has clearing away heat and cooling blood, the effect of blood circulation promoting and blood stasis dispelling, and modern medicine thinks that it has bacteriostasis, antiinflammation and refrigeration function etc.
Paeonol chemical name: Phenanthro [1,2-b] furan-10,11-dione, 6,7,8,9-tetrahydro-1,6,6-trimethyl molecular formula: C9H10O3.
Pharmacological effect: paeonol has analgesia, antiinflammatory, analgesic and suppress allergic effect.To pressing the pain due to physics such as tail, acetic acid or the chemical factor, has significant analgesia role.
(B) potassium nitrate; The desensitization mechanism of potassium salt is: because potassium ion is penetrated on the dental nerve tip, the permeability of ion channel makes the ability of tooth conduction nerve signal weaken on the neurocyte owing to changed, and pain perception is able to alleviate.
(C) strontium carbonate; The desensitization mechanism of strontium carbonate is: strontium carbonate can be produced hydroxyl saamite Ca3 (Po4) 2Sr (0H) 2 with Dentinal hydroxyapatite effect; On the essence surface of wearing and tearing tooth or exposure and be penetrated into the inner insoluble salt crystal that forms; Block and the shielding canaliculi dentales; Slow down the conduction of stimulation, thereby improve the ability of tooth antiallergic.
(D) tranexamic acid; Chemical name: Tranexamic Acid.
Effect: similar with Aminomethylbenzoic Acid.Be used for various hemorrhages, abnormal bleeding etc. during operation.
Pharmacological action: low dosage can suppress the activation of plasminogen.High dose can also directly suppress the activity of the protein resolvase of fibrinolysin, also can suppress the activity of trypsin, Chymotrypsin.With the lysine land of plasminogen or fibrinolysin high affinity is arranged, thus can combine with fibrinolysin by the fibrinous lysine of competitive inhibition, thus the cracking of inhibition fibrin clot produces anastalsis.
The invention has the beneficial effects as follows: the present invention is a kind of control periodontitis; Pain relieving, antianaphylactic formulation of tooth-paste is compared with tooth paste product on the market; Its prescription is to adopt to have " paeonol " of antiinflammation core as product; And potassium salt in addition, strontium salt is used for antiallergic, and ammonia potassium naphthenic acid is used for hemostasis.
The present invention is that to adopt the Chinese medicine ingredients paeonol be the brand-new type toothpaste of main pharmacodynamics composition, is equipped with antiallergic and hemostasis active ingredient, and comparing other chemical synthetic drug, to have zest little, and characteristics such as have no side effect; Integrated and efficient solves oral problem such as periodontitis, hemodia, toothache.Life-time service can improve oral environment, keeps oral health.The present invention fills a prescription rationally, and technology is simple, the result of use highly significant.
The specific embodiment
Below in conjunction with preferred embodiment, to according to the specific embodiment provided by the invention, details are as follows for characteristic:
Embodiment 1 (every part by 1k g)
A kind of medicated toothpaste that is used to treat oral disease; Comprise following composition: water 9.8kg; Glycerol 14kg; Sorbitol 26kg; Xanthan gum 1kg; Cellulose gum 0.5kg; Poloxamer 2.5kg; Saccharin sodium 0.2kg; Methyl hydroxybenzoate 0.1kg; Sodium lauryl sulfate 2.5kg; Allantoin 1kg; Paeonol 0.5kg; Potassium nitrate 5kg; Tranexamic acid 0.05kg; Strontium carbonate 1.5kg; Silicon dioxide 6kg; Calcium hydrogen phosphate 27kg; Zinc citrate 0.8kg; Essence 1.5kg; Light blue 0.0002kg.
The concrete preparation process of medicated toothpaste of the present invention is following:
Step (1) glue (following Water-solubility Material is mixed into translucent sticking shape liquid state):
After the water of the said weight portion of input and poloxamer dissolve fully in agitated reactor, drop into sorbitol, sodium lauryl sulfate, methyl hydroxybenzoate, allantoin, tranexamic acid, the light blue of said weight portion again, fully dissolving was left standstill 20 minutes;
The saccharin sodium of said weight portion is dissolved in 80 ℃ of hot water to dissolving fully, in the input agitated reactor of filtration back;
In premixed device, drop into the glycerol of said weight portion, drop into cellulose gum, xanthan gum, the paeonol of said weight portion again, this mixture back that is uniformly dispersed is dropped in the agitated reactor and evenly stirred 15 minutes with aforementioned mixing of materials, it is subsequent use to process the glue discharging;
Said weight portion potassium nitrate, strontium carbonate are dissolved in 80 ℃ of hot water, stir dissolving back input agitated reactor fully, agitation cycle 20 minutes, this aqueous solution is subsequent use;
Step (2) system cream:
Open cooling water, energized is opened air compressor as the operational power source;
After glue that step (1) is made and aqueous solution add Manufacturing medicine extract machine fully, add powder again and go into Manufacturing medicine extract machine, when adding powder, add said weight portion zinc citrate, silicon dioxide earlier, add the calcium hydrogen phosphate and the essence of said weight portion again, stir; The check of regularlying sample, fill.
Primary raw material source and specification requirement:
Paeonol: purchase in Huangyan, Zhejiang Seiko laboratory content >=99.0 (being not certain supercritical extraction).
Potassium nitrate: Shillong chemical inc (specification: analytical pure).
Strontium carbonate: Shillong Chinese workers limited company (specification: analytical pure).
Tranexamic acid: purchase in Hunan Dongting Pharmaceutical Co., Ltd. content >=99.0.
Embodiment 2: (every part by 1kg)
A kind of medicated toothpaste that is used to treat oral disease, comprise following composition: water 8.6kg, glycerol 17kg, sorbitol 28kg, xanthan gum 1kg, cellulose gum 0.5kg; Poloxamer 2kg, saccharin sodium 0.4kg methyl hydroxybenzoate 0.4kg, sodium lauryl sulfate 3kg, allantoin 2kg, paeonol 0.5kg; Potassium nitrate 3kg, tranexamic acid 0.04kg, strontium carbonate 1.2kg, Silicon stone 3kg; Calcium hydrogen phosphate 28kg, zinc citrate 1kg, essence 1.2kg, light blue 0.0004kg.
Method for preparing and other are with embodiment 1.
Embodiment 3: (every part by 1k g)
A kind of medicated toothpaste that is used to treat oral disease, comprise following composition: water 9kg, glycerol 20kg, sorbitol 22kg, xanthan gum 1.5kg, cellulose gum 0.8kg; Poloxamer 1.5kg, saccharin sodium 0.5kg methyl hydroxybenzoate 0.3kg, sodium lauryl sulfate 1.5kg, allantoin 2.5kg, paeonol 0.8kg; Potassium nitrate 4kg, tranexamic acid 0.08kg, strontium carbonate 1.9kg, Silicon stone 4kg; Calcium hydrogen phosphate 25kg, zinc citrate 1.5kg, essence 1.7kg, light blue 0.0005kg.
Method for preparing and other are with embodiment 1.
Effect:
The present invention has added this Chinese medicine ingredients of paeonol by a certain percentage can suppress the formation that tooth loses; Reduce Dentinal permeability, weaken the liquid flow in the dentinal tubule, reduce stimulation the dental nerve fiber; Stop the sensation conduction, make the tooth symptom of aching be able to alleviate or disappear.Life-time service can improve oral environment, keeps oral health.
Strontium carbonate is penetrated into the teeth roots of exposure through water miscible strontium ion, and the permeability of hard tooth tissue is reduced, thereby slows down the projection conduction of dentin cell's slurry, quickens the formation of secondary dentin, makes pain relief; Potassium nitrate helps out, and can reduce dental sensitivity, improves desensitization effect.Cooperate the anastalsis of tranexamic acid that oral disease is had good result simultaneously.Development test of the present invention has been played Comprehensive Treatment to periodontitis, toothache, hemodia, the effect of treating both the principal and secondary aspects of a disease through effective combination of this several drugs.
5 groups of toothpaste carry out the clinical oral test shown in the his-and-hers watches 1, wherein 2. 3. 4. organize toothpaste and contain single functional component respectively, suffer from periodontitis with 100; Toothache, patient hypersensitive is divided into 5 groups at random, the toothpaste of 1. 2. 3. 4. 5. organizing on probation respectively; Require brush teeth every day 2 times; Each 5 minutes, adhered to result such as following table 13 months.
Table 1 result of the test
| Contrast groups | 1. blank | 2. single paeonol | 3. potassium salt+strontium salt | 4. ammonia potassium naphthenic acid | 5. toothpaste of the present invention |
| No significant change | 7 | 4 | ?2 | 5 | 1 |
| Change not remarkable | 11 | 6 | ?7 | 6 | 0 |
| Change slightly | 2 | 5 | ?5 | 7 | 3 |
| Highly significant | 0 | 5 | ?6 | 2 | 16 |
Conclusion: can know by table 1,1. organize the variation that does not occur highly significant in the blank, though and 2. 3. group compare 1. group some significant change differences arranged; It is comparatively even that but the data that appear distribute in the interval; Significantly effect is not outstanding, and 4. group is to add tranexamic acid especially, though unique anastalsis is arranged; But suppressing toothache, aspects such as allergy but effect are not remarkable.5. group is optimum formula group of the present invention, and result of the test shows that the variation of highly significant accounts for the overwhelming majority, and this explains paeonol, the obvious effect of appearing again really after potassium strontium salt and ammonia potassium naphthenic acid are composite.
Above-mentioned with reference to embodiment to the detailed description that this medicated toothpaste that is used to treat oral disease and preparation method thereof carries out, be illustrative rather than determinate; Therefore in the variation and the modification that do not break away under the general plotting of the present invention, should belong within protection scope of the present invention.
Claims (2)
1. medicated toothpaste that is used to treat oral disease is characterized in that this medicated toothpaste is prepared from following composition:
The composition parts by weight
Glycerol 10-20;
Sorbitol 20-30;
Xanthan gum 0.5-2;
Cellulose gum 0.1-1;
Poloxamer 1-3;
Saccharin sodium 0.1-0.5;
Methyl hydroxybenzoate 0.1-0.5;
Sodium lauryl sulfate 1-3;
Allantoin 1-3;
Paeonol 0.1-1;
Potassium nitrate 1-5;
Tranexamic acid 0.01-0.1;
Strontium carbonate 0.5-2;
Silica 1-6;
Calcium hydrogen phosphate 20-30;
Zinc citrate 0.5-2;
Essence 1-2;
Light blue 0.0002-0.0005;
Water 8-10.
2. method for preparing that is used to treat the medicated toothpaste of oral disease according to claim 1 is characterized in that the practical implementation step is following:
Step (1) glue:
After the water of the said weight portion of input and poloxamer dissolve fully in agitated reactor, drop into sorbitol, sodium lauryl sulfate, methyl hydroxybenzoate, allantoin, tranexamic acid, the light blue of said weight portion again, fully dissolving was left standstill 20 minutes;
The saccharin sodium of said weight portion is dissolved in 80 ℃ of hot water, filters the back and drop in the agitated reactor;
In premixed device, drop into the glycerol of said weight portion, drop into cellulose gum, xanthan gum, the paeonol of said weight portion again, this mixture back that is uniformly dispersed is dropped in the agitated reactor and evenly stirred 15 minutes with aforementioned mixing of materials, it is subsequent use to process the glue discharging;
Said weight portion potassium nitrate, strontium carbonate are dissolved in 80 ℃ of hot water, stir dissolving back input agitated reactor fully, agitation cycle 20 minutes, this aqueous solution is subsequent use;
Step (2) system cream:
After glue that step (1) is made and aqueous solution add Manufacturing medicine extract machine fully, add powder again and go into Manufacturing medicine extract machine, when adding powder, add said weight portion zinc citrate, silicon dioxide earlier, add the calcium hydrogen phosphate and the essence of said weight portion again, stir; The check of regularlying sample, fill.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010101352993A CN101766551B (en) | 2010-03-30 | 2010-03-30 | Drug toothpaste for treating oral diseases and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010101352993A CN101766551B (en) | 2010-03-30 | 2010-03-30 | Drug toothpaste for treating oral diseases and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101766551A CN101766551A (en) | 2010-07-07 |
| CN101766551B true CN101766551B (en) | 2012-05-30 |
Family
ID=42499753
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010101352993A Expired - Fee Related CN101766551B (en) | 2010-03-30 | 2010-03-30 | Drug toothpaste for treating oral diseases and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101766551B (en) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102204874B (en) * | 2011-01-28 | 2012-06-27 | 义乌市爱尚日用品有限公司 | Anti-halitosis toothpaste containing natural drug compound components |
| CN102552061A (en) * | 2012-02-17 | 2012-07-11 | 广东名臣有限公司 | Toothpaste for effectively improving halitosis |
| CN102961278A (en) * | 2012-11-13 | 2013-03-13 | 广西奥奇丽股份有限公司 | Hypoallergenic toothpaste |
| CN103445980B (en) * | 2013-08-24 | 2016-03-02 | 上海方木精细化工有限公司 | Paeonol tooth protection toothpaste |
| CN103494735B (en) * | 2013-09-23 | 2015-05-27 | 淄博齐鼎立专利信息咨询有限公司 | Toothpaste |
| JP6230502B2 (en) * | 2014-07-18 | 2017-11-15 | ライオン株式会社 | Dentifrice composition |
| CN104644460A (en) * | 2015-03-06 | 2015-05-27 | 北京华素制药股份有限公司 | Medicinal toothpaste composition and preparation method and application thereof |
| CN105055247A (en) * | 2015-08-26 | 2015-11-18 | 昆明牙膏有限责任公司 | Toothpaste with hemostasis and gum protection functions and preparation method of toothpaste |
| CN105411871A (en) * | 2015-12-10 | 2016-03-23 | 苏州泽达兴邦医药科技有限公司 | Compound medicine toothpaste |
| CN105560080A (en) * | 2015-12-16 | 2016-05-11 | 郑州人造金刚石及制品工程技术研究中心有限公司 | Efficient whitening toothpaste containing nano carbon crystal |
| CN106924106B (en) * | 2015-12-28 | 2020-11-13 | 天津金士力佳友日化用品有限公司 | Toothpaste for inhibiting dental plaque and relieving gingival inflammation |
| CN105816345A (en) * | 2016-04-20 | 2016-08-03 | 青岛大学附属医院 | Functional toothpaste preparation for preventing and treating periodontitis |
| CN106389142B (en) * | 2016-05-28 | 2019-08-09 | 养美医药有限责任公司 | A kind of Chinese medicinal toothpaste that tooth of releiving is ached |
| CN106983676B (en) * | 2017-03-03 | 2020-06-09 | 广州薇美姿实业有限公司 | Thickening agent for improving stability of oral composition containing zinc salt and application thereof |
| CN108030706A (en) * | 2017-12-15 | 2018-05-15 | 上海美加净日化有限公司 | Double antianaphylaxis tooth paste containing Paeonol and strontium salt |
| US11666532B2 (en) | 2018-01-19 | 2023-06-06 | Hyloris Developments Sa | Tranexamic acid oral solution |
| CN108836888A (en) * | 2018-04-25 | 2018-11-20 | 佛山科学技术学院 | A kind of tooth antiallergic composition |
| CN108685763A (en) * | 2018-08-16 | 2018-10-23 | 苏州清馨健康科技有限公司 | A kind of multiple antiallergic toothpaste |
| CN111568826A (en) * | 2020-05-19 | 2020-08-25 | 四川涑爽医疗用品有限公司 | Oral care composition capable of resisting inflammation, relieving pain and preventing ulcer, oral care toothpaste and preparation method of oral care toothpaste |
| CN113855601A (en) * | 2021-11-05 | 2021-12-31 | 福州幽力克生物科技有限公司 | Toothpaste capable of inhibiting helicobacter pylori and preparation and use method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1331968A (en) * | 2001-07-18 | 2002-01-23 | 广州美晨股份有限公司 | Chinese medicine toothpaste |
| CN1386492A (en) * | 2001-05-18 | 2002-12-25 | 安徽芳草日化股份有限公司 | Natural nursing tooth-paste |
-
2010
- 2010-03-30 CN CN2010101352993A patent/CN101766551B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1386492A (en) * | 2001-05-18 | 2002-12-25 | 安徽芳草日化股份有限公司 | Natural nursing tooth-paste |
| CN1331968A (en) * | 2001-07-18 | 2002-01-23 | 广州美晨股份有限公司 | Chinese medicine toothpaste |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101766551A (en) | 2010-07-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101766551B (en) | Drug toothpaste for treating oral diseases and preparation method thereof | |
| CN102579702B (en) | Medicine for treating dental ulcer and preparation method thereof | |
| TW200524639A (en) | Memantine oral dosage forms | |
| CN102225135B (en) | Traditional Chinese medicine hemostasis powder for external use | |
| JPS6463522A (en) | Pharmaceutical composition for treating and preventing gallstone and gall deficient indigestion | |
| CN103989618B (en) | For toothpaste treating gingivitis and preparation method thereof | |
| CN101757448A (en) | Pure Chinese medicine sterilization anti-inflammatary suspension liniment and preparation method thereof | |
| CN100406063C (en) | External-applied ointment used for treating thyropathy, and its prepn. method | |
| CN101711808B (en) | Soft capsule used for clearing away heat and toxic materials and preparation method thereof | |
| CN1224406C (en) | Medical ointment Jiaoxuanxiao for treating beriberi | |
| KR20220122680A (en) | Compositions and Therapies for the Treatment of Nausea Reflex | |
| CN113713000B (en) | Main medicine component composition for treating sore carbuncle, burn, scald and acne, sustained and controlled release pharmaceutical preparation, and preparation method and application thereof | |
| CN102872169B (en) | Medicine composition for treating chronic rhinitis and preparation method of medicine composition | |
| RU2486901C1 (en) | Polycomponent adhesive ointment for treating erosive lesions of oral mucosa accompanying pemphigus | |
| CN100418542C (en) | Hemorrhoids-treating Chinese traditional medicine | |
| CN1332669C (en) | Dripping pills for reducing swelling and easing pain and its preparing method | |
| CN101468055A (en) | Gel patch for preventing and treating cerebral thrombosis and preparation method thereof | |
| CN105943601A (en) | Traditional Chinese medicine formula for treating haemorrhoids and preparing method thereof | |
| CN1712009A (en) | Externally-applied medicinal liquid for treating acne, rosacea and folliculitis | |
| CN1305839A (en) | Styptic powder | |
| CN101176790B (en) | Percutaneous absorption fortifier | |
| Turner et al. | Drugs Handbook | |
| CN102258554A (en) | New medicine for treating senile dementia | |
| CN117599012A (en) | Preparation method of nose comfort tablet | |
| CN110302236A (en) | Chinese medicine and its preparation method and application for treating nosebleed |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Free format text: FORMER OWNER: TIANJIN TIANSHI BIOENGINEERING CO., LTD. TIANJIN TIANSHI BIOLOGICAL DEVELOPMENT CO., LTD. TIANSHI GROUP CO., LTD., TIANJIN Effective date: 20141216 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20141216 Address after: 301700 Tianjin Wuqing Xinyuan Road North, No. 18 Patentee after: TIANJIN TIANSHI BIOLOGICAL DEVELOPMENT Co.,Ltd. Address before: 301700 Tianjin New Technology Industrial Park Development Zone Wuqing city Wuqing District Road No. 6 source Patentee before: TIANJIN TIANSHI BIOLOGICAL DEVELOPMENT Co.,Ltd. Patentee before: TIANJIN TIANSHI BIOLOGICAL ENGINEERING Co.,Ltd. Patentee before: TIANJIN TIANSHI LIFE-RESOURCES Co.,Ltd. Patentee before: TIANJIN TIANSHI GROUP Co.,Ltd. |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120530 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |